StockGumshoe Alz article, sums up the various drugs in development (and the approved drugs). Unfortunately seems not to have read the data for himself re AVXL. Surprised the stock didn't sell off on this, a lot of people read Gumshoe. I guess those holding it understand the reality of the situation, not Feuerstein/Shkreli lies.

http://www.stockgumshoe.com/2015/12/alzheimers-wrap-up/

Quote:

---

Anavex 2-73, from Anavex (AVXL), has been discussed by Travis on a couple of occasions in the past. The company keeps proclaiming that their drug does wonders in enhancing cognition. In the opinion of the ever-skeptical Doc Gumshoe, their claims are hooey. For example, this past month they announced – to great fanfare – the results of a small uncontrolled clinical trial in which they gave about 50 patients their drug, following which they gave them the usual tests of cognition. The patients did a little better, but there is no way of knowing whether this was because of the drug or a placebo effect. All of the patients in the trial got Anavex 2-73, and it would be entirely to be expected if these patients, pleased and excited to be in a clinical trial of an exciting new drug, actually did do a little better on those instruments. The absence of a placebo group ramps up my skepticism quotient by a factor of ten at least, and the ballyhoo of their announcement by another ten. Anavex has another candidate, Anavex 3-71, which targets the same receptors. So far it has been tested in mice only. This is a Wait and See proposition.

---